EMD Serono
EMD Serono is the U.S. healthcare subsidiary of Merck KGaA, developing and commercializing specialty biopharmaceuticals across neurology, immunology, fertility, oncology, and endocrinology for patients with difficult-to-treat conditions.
- Company typePrivate
- Founded1981
- HeadquartersRockland, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What EMD Serono does
EMD Serono, Inc. is the U.S. healthcare subsidiary of Merck KGaA, Darmstadt, Germany, operating as a specialty biopharmaceutical company focused on developing and commercializing therapies in neurology & immunology, fertility, oncology, and endocrinology. The company was founded in 1981 and employs 1,001–5,000 people, with corporate headquarters in Boston's Seaport District and an R&D Institute in Billerica, Massachusetts. Its marketed portfolio includes MAVENCLAD (cladribine tablets) and Rebif (interferon beta-1a) for multiple sclerosis; Gonal-f, Ovidrel, Cetrotide, and Pergoveris for fertility; BAVENCIO (avelumab) for urothelial carcinoma; TEPMETKO (tepotinib) for METex14-altered metastatic NSCLC; and Serostim for HIV-associated wasting. Technical differentiators include recombinant DNA technology (e.g., one of the first recombinant human FSH products), proprietary drug delivery devices such as the Redi-ject pen, and companion diagnostic integration (FoundationOne CDx for TEPMETKO patient selection).
The company operates a hybrid go-to-market model combining traditional prescription-based specialty distribution through healthcare providers, direct-to-consumer sales through the TrumpRx.gov platform for fertility drugs at up to 84% below list price, specialty pharmacy partnerships (CVS Health), and patient support programs such as MS LifeLines, Fertility Instant Savings, and the Embracing Carers initiative. EMD Serono monetizes through prescription drug sales rather than licensing or SaaS, with pricing models including most-favored-nation unit pricing on the TrumpRx channel and income-tiered discounts. The company is privately held under Merck KGaA, does not disclose standalone revenue, and is governed by its parent's strategic direction, as evidenced by a recent senior leadership transition in which Monia Vial succeeded Andrew Paterson as President of EMD Serono and Head of North America.
EMD Serono firmographics
Firmographics- Name
- EMD Serono
- Legal name
- EMD Serono, Inc.
- Website
- https://emdserono.com
- Company type
- Private
- Founded year
- 1981
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- EMD Serono is the U.S. healthcare subsidiary of Merck KGaA, developing and commercializing specialty biopharmaceuticals across neurology, immunology, fertility, oncology, and endocrinology for patients with difficult-to-treat conditions.
- Ownership category
- akta.pro rank
EMD Serono industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
Keywords
Where EMD Serono is headquartered
LocationHeadquarters
- HQ city
- Rockland
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
EMD Serono business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales
Revenue model
- Prescription Specialty Pharmaceuticals: EMD Serono generates revenue through the sale of prescription specialty pharmaceutical products including MAVENCLAD (cladribine tablets), Rebif (interferon beta-1a), Gonal-f, Ovidrel, Cetrotide, Serostim, BAVENCIO (avelumab), and TEPMETKO (tepotinib). Revenue is generated through traditional pharmaceutical distribution channels with healthcare providers prescribing to patients.
- TrumpRx Direct-to-Consumer Sales: Following the agreement with the Trump administration in October 2025, EMD Serono sells fertility medications directly to consumers at significantly reduced prices through the TrumpRx.gov platform, with discounts of up to 84% below list price.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | TrumpRx MFN Pricing for Fertility Drugs |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
EMD Serono product offering
Product offeringCore offering
EMD Serono develops, manufactures, and commercializes specialty biopharmaceutical products across five therapeutic areas: neurology and immunology (multiple sclerosis and myasthenia gravis treatments including MAVENCLAD and Rebif), fertility (Gonal-f, Ovidrel, Cetrotide, and Pergoveris for IVF and infertility treatment), oncology (BAVENCIO for urothelial carcinoma and Merkel cell carcinoma, TEPMETKO for metastatic NSCLC with METex14 alterations), and endocrinology (Serostim for HIV-associated wasting). The company also operates patient support programs, healthcare professional education, and direct-to-consumer access through the TrumpRx government platform.
Differentiator
Problem solved
Functional benefit
Brands
- Embracing Carers: A global initiative in collaboration with leading organizations to increase awareness, discussion and action about the often-overlooked needs of carers.
- MS LifeLines
- MAVENCLAD
- Rebif
Products and services
- MAVENCLAD (cladribine tablets) Short-course oral disease-modifying therapy for adults with relapsing forms of multiple sclerosis (RMS), also under clinical development for generalized myasthenia gravis. Prescribed by neurologists and dispensed through specialty pharmacy channels.
- Rebif (interferon beta-1a subcutaneous injection) Subcutaneous injectable disease-modifying therapy for relapsing forms of multiple sclerosis, supported by the MS LifeLines patient support program providing education, treatment information, and financial assistance.
- Gonal-f (follitropin alfa) Recombinant human follicle-stimulating hormone used to stimulate ovulation in women undergoing fertility treatment including IVF, administered via the proprietary Redi-ject pre-filled pen. Offered at significantly reduced prices through the TrumpRx platform.
- Ovidrel (choriogonadotropin alfa) Recombinant human chorionic gonadotropin used to trigger final follicular maturation and ovulation in fertility treatment cycles. Offered at significantly reduced prices through the TrumpRx platform.
- Cetrotide (cetrorelix) GnRH antagonist used to prevent premature ovulation during controlled ovarian stimulation in fertility treatment cycles. Offered at significantly reduced prices through the TrumpRx platform.
- Pergoveris (follitropin alfa and lutropin alfa) Combination therapy of recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone for women with severe FSH and LH deficiency undergoing fertility treatment, currently filing for U.S. approval under expedited FDA review.
- BAVENCIO (avelumab) PD-L1 immune checkpoint inhibitor for treatment of locally advanced or metastatic urothelial carcinoma (first-line maintenance) and Merkel cell carcinoma, administered by healthcare professionals in oncology settings.
- TEPMETKO (tepotinib) Once-daily oral MET inhibitor for treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations, identified via the FDA-approved FoundationOne CDx companion diagnostic.
- Serostim (somatropin) Recombinant human growth hormone indicated for the treatment of HIV-associated wasting or cachexia in patients receiving antiretroviral therapy, supported by the AXIS Center patient support program.
Quantifiable outcome
- 6+ million IVF babies helped since first success
- +3 more outcomes
Companies that use EMD Serono
Customer profileNamed customers3 records
Segments6 records
Ideal customer profiles2 records
EMD Serono technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature3 records
EMD Serono partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Foundation MedicinecoreFDA approved FoundationOne CDx as companion diagnostic for TEPMETKO (tepotinib) to identify metastatic NSCLC patients with METex14 skipping alterations. This marked the first time Foundation Medicine leveraged real-world data from its Flatiron Health-Foundation Medicine Clinico-genomic Database to support regulatory approval.
- Trump Administration / TrumpRxcoreEMD Serono entered a most-favored-nation pricing agreement with the Trump administration to offer fertility therapies (Gonal-f, Ovidrel, Cetrotide) at up to 84% below list price through the TrumpRx.gov direct-to-consumer platform. The company also received exclusion from pharmaceutical tariffs in exchange for U.S. biopharmaceutical manufacturing investments. The agreement includes an FDA CNPV priority review voucher for Pergoveris.
- CVS HealthcoreCVS Health announced partnership in the TrumpRx Fertility program through its CVS Specialty Pharmacy, expected to launch January 2026. The program aims to reduce medicine costs and simplify access for patients requiring IVF medications, with Gonal-F available at 84% reduction.
- FDAcoreEMD Serono received one of the first nine Commissioner's National Priority Review Vouchers (CNPVs) from FDA, enabling expedited review of Pergoveris fertility treatment filing.
- RESOLVE: The National Infertility AssociationcoreEMD Serono collaborates with RESOLVE as a Visionary Partner and Corporate Council member to advance awareness, provide resources, and destigmatize infertility. The partnership focuses on patient education and support for people undergoing fertility treatment.
- Accelerated Cure Project for Multiple Sclerosis (ACP)coreEMD Serono collaborates with ACP, a patient-founded non-profit dedicated to accelerating MS research, where individuals living with MS provide feedback on patient-reported outcome endpoints in clinical trials and patient-facing materials.
- Myasthenia Gravis Foundation of America (MGFA) and Myasthenis Gravis Association (MGA)coreEMD Serono collaborates with MGFA and MGA for patient community engagement in myasthenia gravis, participating in MG-strong congresses and working to understand the rare autoimmune neuromuscular disorder better.
- Embracing Carers Global AdvisorscoreGlobal initiative including advisors: Caregiver Action Network, Carers Australia, Carers Canada, Carers UK, Carers Worldwide, Eurocarers, National Alliance for Caregiving, International Alliance of Carer Organizations (IACO), Shanghai Roots & Shoots China. The initiative aims to increase global awareness, broaden stakeholder engagement, engage healthcare systems, and drive policy focus on caregiving.
Scale indicators5 records
Recent moves8 records
Expansion highlights7 records
EMD Serono competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Specialty pharma leader with deep immunology (Humira/Skyrizi/Rinvoq) and women's health presence, operating at significantly broader scale across EMD Serono's therapeutic verticals.
- Sanofi (Specialty Care / Genzyme): Diversified global pharma whose specialty care unit focuses on rare diseases, neurology, and immunology, overlapping EMD Serono's neurology/immunology franchises at broader scale.
- Bayer (Pharmaceuticals): Diversified pharma with women's health, oncology, and specialty care units, offering broad-based overlap with EMD Serono's therapeutic mix.
- Novartis Pharmaceuticals: Large pharma with specialty oncology, neurology (Kesimpta, Mayzent in MS) and reproductive health assets, providing indirect competition across multiple EMD Serono therapeutic areas.
Direct peers
- Astellas Pharma: Specialty pharma with oncology, rare disease and women's health franchises, including targeted oncology therapies comparable to EMD Serono's TEPMETKO.
- Organon & Co: Women's-health focused specialty pharma built around reproductive health, fertility, and established brands; closely comparable to EMD Serono's fertility franchise and reproductive endocrinology business.
- Ipsen Biopharmaceuticals: Specialty pharma focused on oncology, neurology, and rare diseases; comparable therapeutic mix to EMD Serono and recent employer of EMD Serono's incoming President, indicating cultural overlap.
- Teva Pharmaceutical Industries: Specialty pharma with an MS franchise (Copaxone) and broad neurology/inflammation presence, directly comparable to EMD Serono's MS and immunology portfolio.
- Biogen: Specialty pharma with an MS franchise (Tysabri, Tecfidera, Avonex) and rare/neurology focus, directly comparable to EMD Serono's MS franchise and immuno-neurology pipeline.
Emerging players
- Swedish Orphan Biovitrum (Sobi): Rare-disease specialty pharma focused on immunology, neurology, and hematology; emerging player with partial overlap to EMD Serono's rare autoimmune (gMG) and inflammation pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
EMD Serono social profiles
Digital presenceEMD Serono financial estimates
Financial estimateRevenue estimate
Valuation estimate
EMD Serono leadership team
Management profileNumber of profiles
Profiles8 records
EMD Serono funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EMD Serono M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EMD Serono
What does EMD Serono do?
EMD Serono develops, manufactures, and commercializes specialty biopharmaceutical products across five therapeutic areas: neurology and immunology (multiple sclerosis and myasthenia gravis treatments including MAVENCLAD and Rebif), fertility (Gonal-f, Ovidrel, Cetrotide, and Pergoveris for IVF and infertility treatment), oncology (BAVENCIO for urothelial carcinoma and Merkel cell carcinoma, TEPMETKO for metastatic NSCLC with METex14 alterations), and endocrinology (Serostim for HIV-associated wasting). The company also operates patient support programs, healthcare professional education, and direct-to-consumer access through the TrumpRx government platform.
Is EMD Serono a public or private company?
EMD Serono is a private company. It is classified as corporate owned and is currently operating.
When was EMD Serono founded?
EMD Serono was founded in 1981. It employs 1,001 to 5,000 people.
Where is EMD Serono based?
EMD Serono is headquartered in Rockland, United States, in the North America region.
How does EMD Serono make money?
Two revenue lines are on record. Prescription Specialty Pharmaceuticals are the primary driver. The others are trumpRx Direct-to-Consumer Sales.
Who are EMD Serono's main competitors?
Broad incumbents on record are AbbVie, Sanofi (Specialty Care / Genzyme), Bayer (Pharmaceuticals) and Novartis Pharmaceuticals. Direct peers are Astellas Pharma, Organon & Co, Ipsen Biopharmaceuticals, Teva Pharmaceutical Industries and Biogen. Swedish Orphan Biovitrum (Sobi) is listed as an emerging player.
Does EMD Serono have an API?
No public API is recorded for EMD Serono.
What industry is EMD Serono in?
EMD Serono's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.